Skip to main content
. Author manuscript; available in PMC: 2012 Aug 16.
Published in final edited form as: Oncogene. 2011 Jul 11;31(7):828–841. doi: 10.1038/onc.2011.277

FIGURE 5. Proteasome independent but p53-dependent downregulation of E2F1 by functional loss of MDM2.

FIGURE 5

A, E2F-1 downregulation with siRNA pools. Scrambled siRNA pools are shown as reference controls. B, Comparative analysis of cell growth in indicated melanoma cell lines following introduction of the indicated siRNAs. C, Representative brightfield microphotographs (72 h) of control siRNA (siRNA-C) and E2F1 siRNA (siE2F1) in SK-Mel-147 and UACC62 cells. D, loss of E2F-1 is not dependent upon proteasomal degradation as shown by protein immunoblots following Nutlin-3 treatment in the presence or absence of the proteasome inhibitor Bortezomib (Brtz, 10 nM). MCL-1 and ubiquitin (Ub) are shown as controls for proteasomal inhibition. E, Protein immunoblots depicting time-dependent effects of Nutlin-3 (5 μmol/L) treatment following infections with Control, p16, p21 or p53 shRNA lentiviral constructs in SK-Mel-103.